MD Acumen · Pivotal Guideline Bundle
Eight UK primary-care guideline shifts you need to know · 2024–2026
Diabetes & cardiometabolic medicine
1 · Diabetes prescribing · UK backbone
NICE NG28 — Type 2 diabetes in adults: management
National Institute for Health and Care Excellence · last updated 18 February 2026
Practice change
For adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), triple therapy first-line — metformin + SGLT2 inhibitor + subcutaneous semaglutide (Ozempic up to 1 mg/wk). Dual therapy (metformin + SGLT2i) first-line for adults without CV/renal comorbidity. Material shift from the previous stepwise model.
Taught in: PGCert in DCRM, Unit 1 + Unit 2 · DCRM Mini-module · Sample DCRM Synoptic (Item 1).
Lipid management & cardiovascular prevention
2 · Dyslipidaemia · European backbone (newest)
2025 ESC/EAS Focused Update on dyslipidaemia management
Mach F, Koskinas KC, Roeters van Lennep JE et al. · Eur Heart J 2025;46:4359–4378 · DOI: 10.1093/eurheartj/ehaf190
Practice change
Five practice-changing recommendations: (i) bempedoic acid is Class I for statin-intolerant patients (CLEAR Outcomes); (ii) Lp(a) >50 mg/dL (>105 nmol/L) is a Class IIa CV risk-enhancing factor in all adults; (iii) lifetime Lp(a) measurement recommended at least once; (iv) high-dose icosapent ethyl Class IIa for residual hypertriglyceridaemia on statin; (v) Class I statin therapy in primary prevention for people with HIV ≥40y (REPRIEVE).
Taught in: PGCert in DCRM, Unit 3 · DCRM Mini-module Vignette 3 (familial hypercholesterolaemia + elevated Lp(a)) · Sample DCRM Synoptic (Item 4).
Chronic kidney disease & cardiorenal protection
3 · CKD · International backbone
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Levin A, Stevens PE et al. · Kidney International, March 2024
Practice change
Updated CKD definition and risk-stratification using SCORE2-Diabetes + cystatin-C-based eGFR. Confirms SGLT2 inhibitor as cornerstone for CKD with proteinuria, irrespective of diabetes status. Statin recommended for adults >50 with CKD. UK-implementation pathway anchored on NICE NG203 + NICE TA877 finerenone for stage 3–4 CKD with albuminuria + T2D.
Taught in: PGCert in DCRM, Unit 4 · DCRM Mini-module Vignette 1 (cardiorenal CKD) · Sample DCRM Synoptic (Item 3) · published in Varma & Ravindran, InnovAiT 2026.
Metabolic-dysfunction-associated steatotic liver disease (MASLD)
4 · MASLD · Joint European backbone
EASL–EASD–EASO 2024 Clinical Practice Guidelines on MASLD
European Association for the Study of the Liver, EASD, EASO · J Hepatol 2024;81:492–542
Practice change
Renames NAFLD → MASLD and NASH → MASH. Case-finding in T2D, obesity, abnormal LFTs using stepwise FIB-4 → vibration-controlled transient elastography (FIB-4 <1.3 low; 1.3–2.67 intermediate → VCTE; >2.67 → hepatology). Incretin therapy (semaglutide, tirzepatide) for comorbid T2D/obesity. Resmetirom Class IIa for non-cirrhotic MASH with significant fibrosis (≥F2) where licensed.
Taught in: PGCert in DCRM, Unit 3 + Unit 4 · DCRM Mini-module · Sample DCRM Synoptic (Item 7) · published in Robb, Ravindran & Varma, InnovAiT 2026.
Menopause, HRT & mid-life hormonal medicine
5 · Menopause · UK pivotal backbone
NICE NG23 Menopause: identification and management (Nov 2024 update) + BMS Tools for Clinicians: HRT Guide (Feb 2026)
National Institute for Health and Care Excellence + British Menopause Society · most current UK practical-prescribing instrument is the BMS HRT Guide (Feb 2026)
Practice change
Quantified breast-cancer risk anchored against lifestyle comparators in shared-decision communication. Transdermal oestrogen preferred over oral in raised-BMI / VTE-risk women. Micronised progesterone the BMS-preferred progestogen. Premature ovarian insufficiency: HRT (or COC if contraception needed) until at least age 51. NICE TA1143 fezolinetant (Mar 2026) now licensed for moderate-to-severe vasomotor symptoms in selected patients — material non-hormonal option, especially in tamoxifen-treated breast-cancer survivors.
Taught in: PGCert in Menopause & Andropause, Units 1–3 · M&A Mini-module · Sample M&A Synoptic (Item 3 fezolinetant; Item 6 risk communication) · published in Ravindran & Varma, InnovAiT 2026.
Integrating diabetes, cardiology, nephrology & metabolic medicine
6 · DCRM integration · International consensus
DCRM 2.0 Multispecialty Practice Recommendations
Handelsman Y, Anderson J, Bakris G et al. (incl. Kausik Ray, Naveed Sattar, Kamlesh Khunti, Peter Grant, John Wilding) · Metabolism 2024;159:155931
Practice change
A 22-graphic multispecialty consensus integrating AHA / ACC / ESC / NICE / ADA / EASD / KDIGO best-practice care pathways into a single primary-care-facing framework for diabetes, cardiorenal and metabolic diseases. Provides the integrative meta-document that sits coherently alongside the individual disease-specific guidelines — closing the historical primary-care gap between specialty silos.
Taught in: PGCert in DCRM, structural spine across all four units · DCRM Mini-module · embedded as adapted-schematic on the PGCert DCRM page.
Headache & migraine medicine
7 · Migraine prevention · CGRP-targeted TA set
NICE CG150 (Mar 2021) + complete NICE Technology Appraisal set for CGRP-targeted therapies and gepants
TA682 erenumab · TA764 fremanezumab · TA659 galcanezumab · TA871 eptinezumab · TA952 atogepant · rimegepant (acute + preventive) · TA260 botulinum toxin A
Practice change
The chronic-migraine preventive armamentarium has expanded across four CGRP monoclonal antibodies + two oral gepants for prevention in 2020–2025, plus botulinum toxin type A. As of 2024–2025, NICE confirms 20,000+ UK patients now benefit from the new pill class. International alignment: EHF Ornello et al. 2025 evidence-based pharmacological framework; AHS 2024 Position Statement; Ashina M, Nat Rev Dis Primers Migraine 2022.
Taught in: PGCert in Clinical Headache Management, Unit 3 · Headache Mini-module · Sample Headache Synoptic (Item 7).
UK regulatory restrictions you must apply now
8 · Migraine prevention · MHRA topiramate
MHRA topiramate safety communication · January 2024
UK Medicines and Healthcare products Regulatory Agency · Drug Safety Update
Practice change
Topiramate must not be used during pregnancy or in females of child-bearing potential unless conditions of the Pregnancy Prevention Programme are met (January 2024 restriction). Aligns topiramate restrictions with the long-standing valproate Pregnancy Prevention Programme (further tightened in 2024 to also restrict valproate initiation in males under 55). High-frequency prescribing trap for UK primary care; reframes first-line oral migraine prevention in women of child-bearing age.
Taught in: PGCert in Clinical Headache Management, Unit 2 · Headache Mini-module · Sample Headache Synoptic (Item 6 migraine prevention oral first-line).
Test yourself against this canon — free Sample Synoptics
Three Acumen Sample Synoptics test contemporary UK primary-care reasoning against the guidelines above. 15 single-best-answer items each. Free, professor-authored, metacognitive feedback per item. mdacumen.com/academy/synoptics
Where would you like to go next?
Explore the credentialled-PGCert programmes that teach this canon in structured FHEQ Level 7 form, or open an enquiry directly with the Director.